NCT07918079
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Standard antiemetic regimen consisting of netupitant/palonosetron (NEPA), dexamethasone, and olanzapine administered on Days 1-4 (Day 5: observation only). No extended NEPA dosing is given from Day 6 through Day 21.
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6, 11, and 16.
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6 and 13.
Drugs: Netupitant and Palonosetron, Dexamethasone, Olanzapine 5 Mg ORAL TABLET